MCID: CLL014
MIFTS: 45

Cll/sll

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Cll/sll

MalaCards integrated aliases for Cll/sll:

Name: Cll/sll 12 15
Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma 12 70

Classifications:



External Ids:

Disease Ontology 12 DOID:6354
NCIt 50 C27911
SNOMED-CT 67 399607007
UMLS 70 C1302547

Summaries for Cll/sll

Disease Ontology : 12 A chronic lymphocytic leukemia that is characterized by the presence of immature lymphocytes in the blood and bone marrow and/or in the lymph nodes.

MalaCards based summary : Cll/sll, also known as chronic lymphocytic leukemia/small lymphocytic lymphoma, is related to merkel cell carcinoma and anemia, autoimmune hemolytic, and has symptoms including fatigue An important gene associated with Cll/sll is ZAP70 (Zeta Chain Of T Cell Receptor Associated Protein Kinase 70), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Venetoclax and rituximab have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, breast and thyroid, and related phenotypes are Reduced mammosphere formation and hematopoietic system

Related Diseases for Cll/sll

Diseases related to Cll/sll via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 264)
# Related Disease Score Top Affiliating Genes
1 merkel cell carcinoma 30.7 TP53 PDCD1 PAX5
2 anemia, autoimmune hemolytic 30.5 ZAP70 IGHV4-38-2 CD5 CD19 CCR6
3 angioimmunoblastic t-cell lymphoma 30.4 PDCD1 MME BCL6
4 macroglobulinemia 30.3 TP53 PAX5 BTK
5 leukemia, chronic lymphocytic 2 30.3 ZAP70 CD5 CD38 ATM
6 hairy cell leukemia 30.2 TP53 CD5 CD38 CD22 CCND1
7 follicular lymphoma 30.2 MME EZH2 CD5 CCND1 BCL6
8 agammaglobulinemia 30.1 CD79B CD79A CD19 BTK
9 prolymphocytic leukemia 30.1 ZAP70 TP53 CD5 CD38 CD19 CCND1
10 plasmablastic lymphoma 30.0 CD38 BCL6
11 lymphoblastic lymphoma 29.9 TP53 PAX5 MME CD5 BCL6
12 myeloid sarcoma 29.8 SPN PAX5 CD79A
13 richter's syndrome 29.7 ZAP70 TP53 SPN IGHV4-38-2 CD5 CD38
14 composite lymphoma 29.6 PAX5 MME IGHV4-38-2 CD79A CD5 CD22
15 nodal marginal zone lymphoma 29.6 SPN MME IGHV4-38-2 CD5 BCL6
16 autoimmune disease 29.6 ZAP70 PDCD1 CD79A CD22 CCR6
17 skin carcinoma 29.5 TP53 PDCD1 MME LEF1 CCR6 CCND1
18 lymphoma 29.0 TP53 PDCD1 PAX5 EZH2 CD5 CD38
19 peripheral t-cell lymphoma 28.8 TP53 PDCD1 PAX5 MME CD5 CD38
20 mantle cell lymphoma 28.5 TP53 SPN PAX5 MME EZH2 CD5
21 myeloma, multiple 28.4 TP53 IGHV4-38-2 EZH2 CD5 CD38 CD19
22 immune deficiency disease 28.3 ZAP70 SPN PDCD1 CD79A CD5 CD38
23 b-cell lymphoma 28.2 ZAP70 TP53 PAX5 MME EZH2 CD79B
24 lymphoplasmacytic lymphoma 28.2 PAX5 MME IGHV4-38-2 CD79B CD79A CD5
25 leukemia, acute lymphoblastic 27.8 ZAP70 TP53 PAX5 MME LEF1 IGHV4-38-2
26 diffuse large b-cell lymphoma 27.4 TP53 SPN PDCD1 PAX5 MME EZH2
27 marginal zone b-cell lymphoma 27.0 SPN PAX5 MME IGHV4-38-2 CD79B CD79A
28 leukemia, chronic lymphocytic 26.8 ZAP70 TP53 SPN PAX5 MME LEF1
29 leukemia, acute myeloid 26.7 TP53 SPN PAX5 MME IGHV4-38-2 EZH2
30 lymphoma, non-hodgkin, familial 25.9 TP53 SPN PAX5 MME IGHV4-38-2 EZH2
31 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.2
32 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 11.2
33 sarcoma 10.6
34 thrombocytopenia 10.6
35 spindle cell sarcoma 10.6
36 hemolytic anemia 10.5
37 lymphoproliferative syndrome 10.4
38 thrombocytopenia due to platelet alloimmunization 10.4
39 lymphadenitis 10.4
40 langerhans cell sarcoma 10.4
41 herpes simplex 10.4
42 esophageal leukoplakia 10.4 TP53 CCND1
43 pancreatic foamy gland adenocarcinoma 10.4 TP53 CCND1
44 esophagus verrucous carcinoma 10.4 TP53 CCND1
45 leukemia 10.4
46 pancytopenia 10.4
47 glomerulonephritis 10.4
48 amyloidosis 10.4
49 lymphomatoid papulosis 10.4
50 synchronous bilateral breast carcinoma 10.3 TP53 CCND1 ATM

Graphical network of the top 20 diseases related to Cll/sll:



Diseases related to Cll/sll

Symptoms & Phenotypes for Cll/sll

UMLS symptoms related to Cll/sll:


fatigue

GenomeRNAi Phenotypes related to Cll/sll according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 ATM BCL6 CCND1 CCR6 CD22 CD5

MGI Mouse Phenotypes related to Cll/sll:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.32 ATM BCL6 BTK CCND1 CCR6 CD19
2 immune system MP:0005387 10.3 ATM BCL6 BTK CCND1 CCR6 CD19
3 cellular MP:0005384 10.28 ATM BCL6 BTK CCND1 CD19 CD22
4 integument MP:0010771 10 ATM BCL6 BTK CCND1 CD19 CD5
5 neoplasm MP:0002006 9.85 ATM BTK CCND1 CD19 CD79A EZH2
6 nervous system MP:0003631 9.77 ATM CCND1 CCR6 CD19 CD22 CD5
7 normal MP:0002873 9.36 BCL6 CCND1 CCR6 CD19 CD5 CD79A

Drugs & Therapeutics for Cll/sll

Drugs for Cll/sll (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Venetoclax Approved, Investigational Phase 3 1257044-40-8 49846579
2
rituximab Approved Phase 3 174722-31-7 10201696
3
Zanubrutinib Approved, Investigational Phase 3 1691249-45-2
4
ofatumumab Approved Phase 3 679818-59-8 6918251
5 Antirheumatic Agents Phase 3
6 Alkylating Agents Phase 3
7 Protein Kinase Inhibitors Phase 3
8 Bendamustine Hydrochloride Phase 3
9
Vidarabine Approved, Investigational Phase 2 24356-66-9 32326 21704
10
Adenosine Approved, Investigational Phase 2 58-61-7 60961
11
Pentostatin Approved, Investigational Phase 2 53910-25-1 40926 439693
12
Erythromycin Approved, Investigational, Vet_approved Phase 2 114-07-8 12560
13
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
14
alemtuzumab Approved, Investigational Phase 2 216503-57-0
15
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
16
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
17
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
18
Pyrimethamine Approved, Investigational, Vet_approved Phase 1, Phase 2 58-14-0 4993
19
Levoleucovorin Approved, Investigational Phase 1, Phase 2 68538-85-2 149436
20
Thalidomide Approved, Investigational, Withdrawn Phase 1, Phase 2 50-35-1 5426
21
Idelalisib Approved Phase 2 870281-82-6
22
Pembrolizumab Approved Phase 2 1374853-91-4
23
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
24
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
25
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
26
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
27
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
28
Obinutuzumab Approved, Investigational Phase 2 949142-50-1
29
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
30
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
31
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
32
Molgramostim Investigational Phase 2 99283-10-0
33
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
34
Sapacitabine Investigational Phase 2 151823-14-2
35 Janus Kinase Inhibitors Phase 2
36 Antiviral Agents Phase 2
37 Erythromycin Estolate Phase 2
38 Erythromycin stearate Phase 2
39 Erythromycin Ethylsuccinate Phase 2
40 Anti-Infective Agents Phase 1, Phase 2
41 Folic Acid Antagonists Phase 1, Phase 2
42 Vitamin B9 Phase 1, Phase 2
43 Antiparasitic Agents Phase 1, Phase 2
44 Vitamin B Complex Phase 1, Phase 2
45 Antimalarials Phase 1, Phase 2
46 Antiprotozoal Agents Phase 1, Phase 2
47 Folate Phase 1, Phase 2
48 Immunologic Factors Phase 2
49 Heptavalent Pneumococcal Conjugate Vaccine Phase 2
50 Antimetabolites Phase 2

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01578707 Phase 3 ofatumumab;ibrutinib
2 Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01611090 Phase 3 Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
3 A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
4 A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07 Completed NCT02049515 Phase 3 IPI-145 (duvelisib);Ofatumumab
5 Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study Recruiting NCT04269902 Phase 3 Venetoclax
6 A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) Recruiting NCT04666038 Phase 3 LOXO-305;Idelalisib;Bendamustine;Rituximab
7 An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL) Recruiting NCT03336333 Phase 3 Zanubrutinib;Bendamustine;Rituximab;Venetoclax
8 A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO) Active, not recruiting NCT02004522 Phase 3 Duvelisib;Ofatumumab
9 Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis Completed NCT00001586 Phase 2 Fludarabine phosphate
10 A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Completed NCT03206918 Phase 2 Zanubrutinib
11 Administration of Jakafi (Ruxolitinib) to Patients With Previously Untreated High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): A Phase II Clinical Trial Completed NCT03041636 Phase 2 Ruxolitinib;Ruxolitinib Phosphate
12 Phase II Trial of Pentostatin, Cyclophosphamide, and Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Completed NCT01024010 Phase 2 Cyclophosphamide;Pentostatin
13 An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia Completed NCT01217749 Phase 1, Phase 2 PCI-32765;ofatumumab
14 Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) With Pentostatin, Alemtuzumab, and Low Dose Rituximab: A Phase II Clinical Trial Completed NCT00669318 Phase 2 pentostatin;sargramostim
15 Phase II Trial of Perifosine in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT00873457 Phase 2 perifosine
16 A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma Completed NCT01403636 Phase 2 SAR245409
17 Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) With Everolimus (RAD001) and Alemtuzumab: A Phase I/II Study Completed NCT00935792 Phase 1, Phase 2 alemtuzumab;everolimus
18 Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 and the Combinations CC-122 AND Ibrutinib and CC-122 and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT02406742 Phase 1, Phase 2 CC-122;CC-122;Ibrutinib;CC-122;Obinutuzumab
19 A Phase II Study of Lenalidomide Revlimid(Registered Trademark) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT00439231 Phase 2 Lenalidomide
20 A Phase II Trial Of Arsenic Trioxide (TRISENOX) In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT00193518 Phase 2 Arsenic Trioxide
21 Combination of Lenalidomide and Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Completed NCT01002755 Phase 2 Lenalidomide
22 Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL Completed NCT01515176 Phase 1, Phase 2 Dinaciclib
23 Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL Completed NCT00974233 Phase 2 Bendamustine;Rituximab;Lenalidomide
24 Randomized Phase 2 Study Comparing Acalabrutinib to Acalabrutinib and Obinutuzumab in the Treatment of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are at High Risk of Disease Progression Recruiting NCT03516617 Phase 2 Acalabrutinib
25 A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) Recruiting NCT03740529 Phase 1, Phase 2 LOXO-305;Venetoclax;Rituximab
26 A Phase II Study of Intermittent Duvelisib Dosing in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Recruiting NCT03961672 Phase 2 Duvelisib
27 BTK Inhibitor Zanubrutinib (BGB-3111) in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) Recruiting NCT04458610 Phase 2 Zanubrutinib
28 A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib Recruiting NCT04116437 Phase 2 Zanubrutinib
29 MRD-Guided Abbreviation of Bendamustine and Rituximab Chemotherapy in Combination With Copanlisib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting NCT04155840 Phase 2 Copanlisib;Bendamustine
30 A Phase I/II Study of Pyrimethamine, a STAT3 Inhibitor, for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recruiting NCT01066663 Phase 1, Phase 2 pyrimethamine
31 A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Presence of 17p Deletion Recruiting NCT02966756 Phase 2 Venetoclax
32 Early Clonal Dynamics During Venetoclax Treatment for Chronic Lymphocytic Leukemia (CLL) Recruiting NCT03986034 Phase 2 During Venetoclax
33 A Prospective, Multicenter, Phase-II Trial of Venetoclax Plus Acalabrutinib in Patients Who Have Relapsed After First Line Venetoclax + Anti-CD20 mAb Treatment for Chronic Lymphocytic Leukemia (CLL or SLL) Recruiting NCT04523428 Phase 2 Venetoclax/Acalabrutinib
34 Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL Recruiting NCT03379051 Phase 1, Phase 2 Venetoclax;Umbralisib;Lenalidomide
35 Phase II Study of Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated CLL/SLL Recruiting NCT03788291 Phase 2 Acalabrutinib;Rituximab
36 Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease by Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL/SLL Patients Recruiting NCT04419519 Phase 2 Venetoclax monotherapy;Venetoclax with anti CD20 monoclonal antibody
37 A Phase Ib/II Study of the Safety, Pharmacokinetic, Pharmacodynamic and Efficacy of APG-2575 Single Agent and in Combination With Other Therapeutic Agents in Patients With Relapsed/Refractory CLL/SLL Recruiting NCT04494503 Phase 1, Phase 2 APG-2575;Rituximab;Ibrutinib
38 First Line Treatment With VeNEtoclaX and ibruTinib Induction Followed by Obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients Not in Complete Remission and/or With Detectable Bone Marrow Minimal Residual Disease (NEXT STEP Trial) Recruiting NCT04639362 Phase 2 ibrutinib, venetoclax, obinutuzumab;ibrutinib, venetoclax
39 Combination of Lenalidomide and Rituximab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy Active, not recruiting NCT01446133 Phase 2 Rituximab;Lenalidomide
40 Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic Features Active, not recruiting NCT01351896 Phase 2 Lenalidomide
41 A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Active, not recruiting NCT02514083 Phase 2 Ibrutinib;Fludarabine
42 Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Active, not recruiting NCT02225275 Phase 2 Lenalidomide
43 A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies Active, not recruiting NCT03010358 Phase 1, Phase 2 Entospletinib
44 A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Active, not recruiting NCT03204188 Phase 2 Ibrutinib;Fludarabine;Pembrolizumab
45 A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Active, not recruiting NCT01145209 Phase 2 Fludarabine Phosphate;Cyclophosphamide
46 Early Intervention Trial of Ibrutinib for Patients With Asymptomatic, High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Active, not recruiting NCT02518555 Phase 2 Ibrutinib
47 Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Active, not recruiting NCT02910583 Phase 2 ibrutinib;placebo to match ibrutinib;venetoclax
48 A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART2019.1 in Patients With Relapsed or Resistant CD20 and CD19 Positive B-NHL Active, not recruiting NCT03870945 Phase 1, Phase 2
49 A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Active, not recruiting NCT03493217 Phase 1, Phase 2 ICP-022
50 A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor Active, not recruiting NCT02639910 Phase 2 Idelalisib;Venetoclax

Search NIH Clinical Center for Cll/sll

Genetic Tests for Cll/sll

Anatomical Context for Cll/sll

MalaCards organs/tissues related to Cll/sll:

40
Bone Marrow, Breast, Thyroid, Myeloid, T Cells, Bone, Lung

Publications for Cll/sll

Articles related to Cll/sll:

(show top 50) (show all 610)
# Title Authors PMID Year
1
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. 61
33216986 2021
2
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. 61
33676628 2021
3
Safety and Antitumor Activity of Acalabrutinib for Relapsed/Refractory B-cell Malignancies: A Japanese Phase I Study. 61
33728735 2021
4
[A study of LEF1 protein expression in diagnosis and differential diagnosis of lymphoblastic lymphoma/acute lymphoblastic leukemia]. 61
33677883 2021
5
Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. 61
33094474 2021
6
Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma. 61
33734005 2021
7
Trends of incidence, mortality and survival for chronic lymphocytic leukaemia / small lymphocytic lymphoma in Switzerland between 1997 and 2016: a population-based study. 61
33793959 2021
8
BTK Inhibitor May Treat Drug-Resistant CLL, SLL. 61
33771769 2021
9
Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group. 61
33618437 2021
10
The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy. 61
32929178 2021
11
Sunlight exposure in association with risk of lymphoid malignancy: a meta-analysis of observational studies. 61
33606147 2021
12
Risk of hematological malignancies in the families of patients treated for nodular lymphocyte-predominant Hodgkin lymphoma. 61
33563316 2021
13
Richter Syndrome. 61
33580422 2021
14
Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants. 61
32818517 2021
15
Small lymphocytic lymphoma mimicking primary cutaneous marginal zone lymphoma with colonization of germinal center follicles. 61
32506455 2021
16
Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors. 61
33570635 2021
17
Angioimmunoblastic T-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Novel Form of Composite Lymphoma Potentially Mimicking Richter Syndrome. 61
33739791 2021
18
Follicular colonization in chronic lymphocytic leukemia/small lymphocytic lymphoma (comment on "Small lymphocytic lymphoma mimicking primary cutaneous marginal zone lymphoma with colonization of germinal center follicles"). 61
33410535 2021
19
Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib. 61
33790574 2021
20
Concomittant occurence of well-differentiated thyroid carcinoma metastasis and chronic lymphocytic leukemia in the same lymph node along with internal jugular vein thrombus: a case report. 61
33433427 2021
21
Primary cutaneous lymphomas in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A series of 12 cases. 61
33415780 2021
22
Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features. 61
32755330 2020
23
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. 61
32762271 2020
24
Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma. 61
32249238 2020
25
Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia. 61
33044848 2020
26
Downregulation of Lymphoid enhancer-binding factor 1 (LEF-1) expression (by immunohistochemistry and/ flow cytometry) in chronic Lymphocytic Leukemia with atypical immunophenotypic and cytologic features. 61
33314668 2020
27
Spindle cell melanoma coexisting with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare collision tumor in multiple sites. 61
32959377 2020
28
Outdoor artificial light at night and risk of non-Hodgkin lymphoma among women in the California Teachers Study cohort. 61
33002844 2020
29
Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice. 61
33311649 2020
30
Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors. 61
33275709 2020
31
Patterns of Human Leukocyte Antigen Class I and Class II Associations and Cancer. 61
33272927 2020
32
Kappa and lambda immunohistochemistry and in situ hybridization in the evaluation of atypical cutaneous lymphoid infiltrates. 61
32870521 2020
33
Collision tumor between a spinal schwannoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: case report and review of the literature. 61
33249871 2020
34
Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis. 61
32880204 2020
35
Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. 61
33054121 2020
36
Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. 61
33022066 2020
37
The relationship between physical activity and lymphoma: a systematic review and meta analysis. 61
33023529 2020
38
Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database. 61
32599988 2020
39
14-Color single tube for flow cytometric characterization of CD5+ B-LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL. 61
32896973 2020
40
Population-based epidemiological data of follicular lymphoma in Poland: 15 years of observation. 61
32884080 2020
41
Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors. 61
32659728 2020
42
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. 61
32209572 2020
43
Bone Marrow Immunohistochemistry and Flow Cytometry in the Diagnosis of Malignant Hematologic Diseases With Emphasis on Lymphomas: A Comparative Retrospective Study. 61
31290784 2020
44
Large Bowel Obstruction in the Setting of Small Lymphocytic Lymphoma. 61
32923240 2020
45
Additional B-cell malignancies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). 61
32175786 2020
46
Simultaneous bone marrow involvement by CLL/SLL and LEF1/cyclin D1-positive metastatic melanoma. 61
32645172 2020
47
Impact of oral oncolytic initiation on medication adherence for pre-existing comorbid chronic conditions. 61
31575355 2020
48
Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes. 61
31523805 2020
49
Assessing Cancer Treatment Information Using Medicare and Hospital Discharge Data among Women with Non-Hodgkin Lymphoma in a Los Angeles County Case-Control Study. 61
32066614 2020
50
Extranodal NK/T cell lymphoma and lymphomatoid granulomatosis in a patient with chronic lymphocytic leukaemia: Case report for a new perspective on Richter syndrome. 61
32384485 2020

Variations for Cll/sll

Expression for Cll/sll

Search GEO for disease gene expression data for Cll/sll.

Pathways for Cll/sll

Pathways related to Cll/sll according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 ZAP70 TP53 PDCD1 MME CD79B CD79A
2
Show member pathways
13.34 ZAP70 TP53 PDCD1 CD79B CD79A CD22
3
Show member pathways
12.61 TP53 CD79B CD79A CD22 CD19 BTK
4
Show member pathways
12.44 CD79B CD79A CD22 CD19 BTK BCL6
5
Show member pathways
12.33 ZAP70 CD22 CD19 BTK BCL6
6
Show member pathways
12.27 CD79B CD79A CD22 CD19 BTK BCL6
7 12.17 TP53 PAX5 BCL6 ATM
8 12.07 ZAP70 PDCD1 PAX5 CD79A CD38 CD19
9 11.83 TP53 LEF1 CCND1 BCL6 ATM
10
Show member pathways
11.68 CD79B CD79A CD22 CD19 BTK
11 11.66 PAX5 LEF1 CCND1
12 11.65 SPN MME CD38 CD19
13 11.58 PDCD1 PAX5 CCR6 BCL6
14 11.55 MME CD5 CD38 CD22 CD19
15 11.46 TP53 LEF1 CCND1
16 11.44 TP53 CCND1 ATM
17 11.37 TP53 CCND1 ATM
18 11.29 SPN MME CD79B CD79A CD5 CD38
19 11.21 TP53 CCND1 ATM
20 11.2 ZAP70 CD79A CD19 BTK

GO Terms for Cll/sll

Cellular components related to Cll/sll according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.8 SPN MME CD79B CD5 CD22 CD19
2 membrane raft GO:0045121 9.35 ZAP70 MME CD79A CD19 BTK
3 external side of plasma membrane GO:0009897 9.28 SPN PDCD1 IGHV4-38-2 CD79B CD79A CD5
4 B cell receptor complex GO:0019815 9.16 CD79B CD79A

Biological processes related to Cll/sll according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.03 TP53 PAX5 LEF1 EZH2 CCND1 BCL6
2 adaptive immune response GO:0002250 9.88 ZAP70 PDCD1 CD79B CD79A CD19 BTK
3 regulation of cell proliferation GO:0042127 9.81 ZAP70 TP53 EZH2 BCL6
4 regulation of immune response GO:0050776 9.77 SPN PDCD1 CD22 CD19 BCL6
5 immune system process GO:0002376 9.76 ZAP70 PDCD1 CD79B CD79A CD19 BTK
6 apoptotic signaling pathway GO:0097190 9.71 CD5 CD38 BTK
7 humoral immune response GO:0006959 9.65 PDCD1 PAX5 CCR6
8 B cell differentiation GO:0030183 9.62 EZH2 CD79B CD79A BCL6
9 somitogenesis GO:0001756 9.61 TP53 LEF1 ATM
10 positive regulation of histone deacetylation GO:0031065 9.57 TP53 BCL6
11 regulation of B cell receptor signaling pathway GO:0050855 9.55 PAX5 CD19
12 mitotic G1 DNA damage checkpoint GO:0031571 9.52 TP53 CCND1
13 T cell migration GO:0072678 9.49 ZAP70 CCR6
14 regulation of T cell migration GO:2000404 9.46 SPN CCR6
15 replicative senescence GO:0090399 9.43 TP53 MME ATM
16 B cell activation GO:0042113 9.26 ZAP70 CD79A CD22 BTK
17 B cell receptor signaling pathway GO:0050853 9.1 IGHV4-38-2 CD79B CD79A CD38 CD19 BTK

Sources for Cll/sll

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....